Evidence map›Paper›PMID 33374450›Full record

ArticleMolecules (Basel, Switzerland)2020

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.

Sahar B Kandil, Christopher McGuigan, Andrew D Westwell

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sahar B KandilSchool of Pharmacy & Pharmaceutical Sciences, Cardiff University, Wales CF10 3NB, UK.ORCID 0000-0003-1806-9623
Christopher McGuiganSchool of Pharmacy & Pharmaceutical Sciences, Cardiff University, Wales CF10 3NB, UK.
Andrew D WestwellSchool of Pharmacy & Pharmaceutical Sciences, Cardiff University, Wales CF10 3NB, UK.ORCID 0000-0002-5166-9236
Cardiff University · GB

Funding

Llywodraeth Cymru no numbers
6 · The paper itself

Abstract

The androgen receptor (AR) is a pivotal target for the treatment of prostate cancer (PC) even when the disease progresses toward androgen-independent or castration-resistant forms. In this study, a series of 15 bicalutamide analogues (sulfide, deshydroxy, sulfone, and

Indexed as

Androgen Receptor AntagonistsAnilidesAntineoplastic AgentsBinding SitesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMaleModels, MolecularMolecular StructureNitrilesProstatic NeoplasmsProtein BindingReceptors, AndrogenAndrogen Receptor AntagonistsAnilidesAntineoplastic AgentsAR protein, humanbicalutamideNitrilesReceptors, AndrogenTosyl Compoundsandrogen receptor (AR)bicalutamidediarylpropionamideprostate cancer (PC)sulfone

Identifiers

PMID33374450
PMCPMC7795644
OpenAlexW3117635268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.